⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1270687 | 1.00 | — | — | |
| SCHEMBL2689072 | 1.00 | — | — | |
| Homocysteine SCHEMBL18770054 | 0.88 | PTGS1 (0.43) | — | |
| SCHEMBL31642611 | 0.86 | FOLH1 (0.44) | — | |
| SCHEMBL31641357 | 0.86 | FOLH1 (0.44) | — | |
| SCHEMBL18881182 | 0.81 | — | — | |
| SCHEMBL19862685 | 0.81 | — | — | |
| SCHEMBL12681624 | 0.81 | — | — | |
| SCHEMBL120068 | 0.80 | — | — | |
| SCHEMBL120067 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010126552-A1 | POTENT CELL-BINDING AGENT DRUG CONJUGATES | IMMUNOGEN, INC. (US) | 2010-11-04 | — | — | WO | claimed |
| US-20100092495-A1 | POTENT CELL-BINDING AGENT DRUG CONJUGATES | IMMUNOGEN INC. (US) | 2010-04-15 | — | — | US | claimed |
| US-7659364-B2 | N-methyl-homocysteines and their use as well as process for their production | CIS BIO INTERNATIONAL (FR) | 2010-02-09 | — | — | US | claimed |
| CN-1304363-C | N-methyl-homocysteines and their use as well as process for their production | CIS BIOLOGY INTERNAT CO (FR) | 2007-03-14 | — | — | CN | claimed |
| CN-1589257-A | N-methyl-homocysteine and application and preparation method thereof | SCHERING AG (DE) | 2005-03-02 | — | — | CN | claimed |
| US-20030120032-A1 | N-methyl-homocysteines and their use as well as process for their production | SCHERING AG (DE) | 2003-06-26 | — | — | US | claimed |
| US-20250222146-A1 | Radiopharmaceuticals Targeting Somatostatin Receptor 2 and Uses Thereof | RAYZEBIO, INC. (US) | 2025-07-10 | — | — | US | disclosed |
| WO-2025137443-A1 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING SOMATOSTATIN RECEPTORS AND USES THEREOF | RAYZEBIO, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| WO-2025137441-A1 | RADIOPHARMACEUTICALS TARGETING SOMATOSTATIN RECEPTOR 2 AND USES THEREOF | RAYZEBIO, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-20190292224-A1 | TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2019-09-26 | — | — | US | disclosed |
| US-10328117-B2 | Bis-sulfhydryl macrocyclization systems | AILERON THERAPEUTICS, INC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-10227380-B2 | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| EP-3432904-A2 | COMPANION DIAGNOSTIC TOOL FOR PEPTIDOMIMETIC MACROCYCLES | Aileron Therapeutics, Inc. (US) | 2019-01-30 | — | — | EP | disclosed |
| US-6333410-B1 | REDUCTIVE HYDROLYSIS OF C3 ESTER WITH LITHIUM TRIMETHOXYALUMINUM HYDRIDE TO YIELD THE MANTANSINOL; ESTERIFYING THE A DISULFIDE-CONTAINING CARBOXYLIC ACID; REDUCING TO YIELD A THIOL-CONTAINING MAYTANSINOID | IMMUNOGEN, INC. | 2001-12-25 | — | — | US | disclosed |
| WO-2001044177-A2 | SOMATOSTATIN ANALOGS, RADIOLABELLED DERIVATIVES THEREOF AND THEIR USE | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-06-21 | — | — | WO | disclosed |
| WO-2001024763-A2 | COMPOSITIONS AND METHODS FOR TREATING CANCER USING IMMUNOCONJUGATES AND CHEMOTHERAPEUTIC AGENTS | IMMUNOGEN, INC. (US) | 2001-04-12 | — | — | WO | disclosed |
| EP-0425235-B1 | Cytotoxic agents comprising maytansinoids and their therapeutic use | IMMUNOGEN INC (US) | 1996-09-25 | — | — | EP | disclosed |
| US-5416064-A | Antitumor agents | IMMUNOGEN, INC. (US) | 1995-05-16 | — | — | US | disclosed |
| US-5208020-A | Cytotoxic agents comprising maytansinoids and their therapeutic use | IMMUNOGEN INC. (US) | 1993-05-04 | — | — | US | disclosed |
| EP-0425235-A2 | Cytotoxic agents comprising maytansinoids and their therapeutic use | IMMUNOGEN INC (US) | 1991-05-02 | — | — | EP | disclosed |